In 2023, Ros et al. showed that the plasmatic BRAFV600E allele fraction (AF) OS was significantly longer in patients with low BRAF AF (< 2%) than in those with high AF (p < 0.0001) Also, patients with high-BRAF AF presented benefit from triplet therapy (HR 0.17, 95% CI 0.06–0.53; interaction test = 0.002) [35]. Here, BRAF is linked to atrial fibrillation.